LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article: Ambrisentan, a non-peptide endothelin receptor antagonist.

    Vatter, Hartmut / Seifert, Volker

    Cardiovascular drug reviews

    2006  Volume 24, Issue 1, Page(s) 63–76

    Abstract: ... of disease states, mainly of the cardiovascular system. Ambrisentan (LU 208075), a selective ET(A)-receptor ... suggest an integral involvement of the endothelin (ET)-system in the pathophysiology of a variety ... antagonist, is an orally active diphenyl propionic acid derivative. It has been shown to have a very ...

    Abstract Increasing numbers of experimental investigations and recently also of clinical trials strongly suggest an integral involvement of the endothelin (ET)-system in the pathophysiology of a variety of disease states, mainly of the cardiovascular system. Ambrisentan (LU 208075), a selective ET(A)-receptor antagonist, is an orally active diphenyl propionic acid derivative. It has been shown to have a very promising efficacy to safety ratio in the initial clinical trials. Phase II and Phase III trials with ambrisentan in pulmonary arterial hypertension have been performed. The pharmacological properties and data from the experimental investigations suggest additional possible uses of ambrisentan in the prevention of reperfusion injury after organ transplantation and in restenosis following coronary artery dilatation. Furthermore, the pharmacological profile of ambrisentan indicates that this drug may also be suitable in the treatment of cerebrovascular disorders. In the present article basic investigations, animal studies and clinical trials with ambrisentan are reviewed. This review may help to define pathophysiological conditions, in which ambrisentan could be indicated and further evaluated in appropriate preclinical and clinical trials.
    MeSH term(s) Animals ; CHO Cells ; Clinical Trials as Topic ; Cricetinae ; Cricetulus ; Endothelin A Receptor Antagonists ; Humans ; Myocardial Ischemia/drug therapy ; Phenylpropionates/chemistry ; Phenylpropionates/pharmacology ; Phenylpropionates/therapeutic use ; Pyridazines ; Renal Insufficiency/drug therapy ; Structure-Activity Relationship
    Chemical Substances Endothelin A Receptor Antagonists ; Phenylpropionates ; Pyridazines ; ambrisentan (HW6NV07QEC)
    Language English
    Publishing date 2006
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 645099-4
    ISSN 0897-5957
    ISSN 0897-5957
    DOI 10.1111/j.1527-3466.2006.00063.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2474: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.

    Badesch, David B / Feldman, Jeremy / Keogh, Anne / Mathier, Michael A / Oudiz, Ronald J / Shapiro, Shelley / Farber, Harrison W / McGoon, Michael / Frost, Adaani / Allard, Martine / Despain, Darrin / Dufton, Christopher / Rubin, Lewis J

    Cardiovascular therapeutics

    2012  Volume 30, Issue 2, Page(s) 93–99

    Abstract: Introduction: Ambrisentan is an oral, once daily, endothelin receptor antagonist approved ... Definitive conclusions regarding the safety and efficacy of ambrisentan in specific non-Group 1 PH etiologies ... observed in several non-Group 1 PH subpopulations. Peripheral edema, headache, and dyspnea were the most ...

    Abstract Introduction: Ambrisentan is an oral, once daily, endothelin receptor antagonist approved for treatment of pulmonary arterial hypertension (PAH). Previous studies of ambrisentan were limited to patients with Group 1 PAH and often excluded patients receiving other pulmonary hypertension (PH) therapies.
    Aims: ARIES-3 was an open-label study evaluating efficacy and safety of ambrisentan in patients with various PH etiologies and background PH medications. Patients received 5 mg ambrisentan once daily for 24 weeks. The primary endpoint was change from baseline in 6-minute walk distance (6MWD) at week 24.
    Results: A total of 224 patients with PH due to idiopathic and familial PAH (31%), connective tissue disease (18%), chronic hypoxemia (22%), chronic thromboembolic disease (13%), or other etiologies (16%) were enrolled and 53% of patients received stable background PAH therapies. After 24 weeks of therapy, an increase in 6MWD (+21 m; 95% CI: 12-29) and a decrease in B-type natriuretic peptide (-26%; 95% CI: -34 to -16%) was observed in the overall population compared to baseline; however, increases in 6MWD were not observed in several non-Group 1 PH subpopulations. Peripheral edema, headache, and dyspnea were the most common adverse events.
    Conclusion: This study reconfirms the results of previous placebo-controlled studies, which demonstrate that ambrisentan is well tolerated and provides benefit in patients with PAH. Definitive conclusions regarding the safety and efficacy of ambrisentan in specific non-Group 1 PH etiologies cannot be determined and larger, controlled studies will be necessary to determine the efficacy and safety of ambrisentan in these populations.
    MeSH term(s) Adult ; Aged ; Double-Blind Method ; Endothelin A Receptor Antagonists ; Exercise Tolerance ; Female ; Humans ; Hypertension, Pulmonary/drug therapy ; Long-Term Care ; Male ; Middle Aged ; Natriuretic Peptide, Brain ; Phenylpropionates/adverse effects ; Phenylpropionates/therapeutic use ; Pyridazines/adverse effects ; Pyridazines/therapeutic use ; Survival ; Treatment Outcome ; Walking/physiology
    Chemical Substances Endothelin A Receptor Antagonists ; Phenylpropionates ; Pyridazines ; Natriuretic Peptide, Brain (114471-18-0) ; ambrisentan (HW6NV07QEC)
    Language English
    Publishing date 2012-04
    Publishing country England
    Document type Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 2428378-2
    ISSN 1755-5922 ; 1755-5914
    ISSN (online) 1755-5922
    ISSN 1755-5914
    DOI 10.1111/j.1755-5922.2011.00279.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2474: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top